IMM27M

DRUG2 trials

Sponsors

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Conditions

Advanced Solid TumorsCTLA4 HaploinsufficiencyHCCOncology

Phase 1

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.CTLA4 Haploinsufficiency, Oncology

Start: 2022-06-15End: 2024-08-30Target: 16Updated: 2023-05-24

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

RecruitingNCT06764836

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Advanced Solid Tumors, HCC

Start: 2024-07-23End: 2026-01-27Target: 108Updated: 2025-01-08

Related Papers

IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation and dose-expansion study.

Journal of Clinical Oncology2025-05-28

Abstract CT097: IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study

Cancer Research2024-04-05

IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study.

Journal of Clinical Oncology2023-06-01